This is an important result that may, in part, explain why most of the current competitive Dyrk1a inhibitors fail to pass the pre-clinical stage with respect to improvement of cognitive impairments in DS (Neumann et al., 2018). This evidence concerns the gene DYRK1A and Dravet syndrome.